Pfizer and BioNTech announced, in a press release published on September 20, the positive results of their clinical trial conducted with 2,268 children between the ages of 5 and 11. Participants received two 10-microgram doses of the vaccine, 21 days apart. It is worth noting that the dose for children over 12 years of age is 30 micrograms.
